OPKO Health (NASDAQ:OPK) Director John Paganelli Sells 9,175 Shares of Company Stock

OPKO Health, Inc. (NASDAQ:OPK) Director John Paganelli sold 9,175 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1.82, for a total transaction of $16,698.50. Following the completion of the transaction, the director directly owned 389,914 shares of the company’s stock, valued at approximately $709,643.48. The trade was a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OPKO Health Stock Down 1.1%

Shares of NASDAQ OPK traded down $0.02 during mid-day trading on Thursday, hitting $1.75. 9,785,748 shares of the stock traded hands, compared to its average volume of 3,240,198. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -19.44 and a beta of 1.52. The stock has a fifty day moving average price of $1.58 and a 200-day moving average price of $1.35. OPKO Health, Inc. has a 52 week low of $0.98 and a 52 week high of $1.83. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%. The firm had revenue of $130.83 million for the quarter, compared to analysts’ expectations of $136.62 million. During the same period in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was down 56.9% compared to the same quarter last year. Research analysts anticipate that OPKO Health, Inc. will post -0.23 EPS for the current year.

Trending Headlines about OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could bolster liquidity as OPKO concentrates on its biotech business. OPKO third-quarter results and business highlights
• Positive Sentiment: OPKO’s reported third-quarter loss was $0.05 per share, better than the $0.07 loss analysts expected, according to one estimate. Zacks report on OPKO’s third-quarter results
• Neutral Sentiment: Following the sale agreement, OPKO forecast 2026 revenue from continuing operations of $268 million to $278 million. OPKO’s 2026 continuing-operations revenue outlook
• Negative Sentiment: Reported third-quarter revenue of $65.4 million was well below FactSet’s $136.6 million estimate, although the earnings-call summary characterized revenue as up 16%. Comparisons may reflect the changing business mix following the planned BioReference sale. Q3 revenue report
• Negative Sentiment: Investors also face biotech execution risk: the earnings-call coverage said losses widened and the CAR-T program timeline was delayed, potentially postponing progress on a key part of OPKO’s future growth strategy. Q3 earnings-call highlights

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OPK. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. Zacks Research upgraded shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a report on Friday, October 16th. Piper Sandler restated an “overweight” rating and set a $4.00 target price (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Finally, UBS Group set a $4.00 target price on shares of OPKO Health in a report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, OPKO Health presently has an average rating of “Moderate Buy” and an average price target of $3.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of OPKO Health in the 2nd quarter worth $55,468,000. AWM Investment Company Inc. acquired a new position in OPKO Health during the 2nd quarter valued at about $3,165,000. Bank of New York Mellon Corp purchased a new stake in OPKO Health in the second quarter valued at about $1,995,000. Bank of America Corp DE raised its stake in OPKO Health by 80.0% in the first quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company’s stock valued at $1,302,000 after buying an additional 507,590 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in OPKO Health by 174.0% in the second quarter. Van ECK Associates Corp now owns 438,645 shares of the biotechnology company’s stock worth $658,000 after acquiring an additional 278,549 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.